NCT05753007 2026-03-16
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
Phase 2 Terminated
Clinical Trials
1,793 trialsNCT04676360 2026-03-13
Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT03386357 2026-03-12
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Erlangen-Nürnberg Medical School
Phase 2 Terminated
NCT04221438 2026-03-12
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT04796324 2026-03-12
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Allarity Therapeutics
Phase 2 Terminated
NCT05744375 2026-03-12
TRANSCENDER
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT03753919 2026-03-11
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Terminated
NCT04832854 2026-03-11
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT04166383 2026-03-10
VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT02946996 2026-03-05
Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Medical University of South Carolina
Phase 2 Terminated
NCT03506373 2026-03-05
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Mayo Clinic
Phase 2 Terminated
NCT04327700 2026-03-05
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
NCT05554354 2026-03-03
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Terminated
NCT03211988 2026-03-02
Entinostat Neuroendocrine (NE) Tumor
Columbia University
Phase 2 Terminated
NCT03514017 2026-03-02
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT05714345 2026-03-02
EXPAND
Allogene Therapeutics
Phase 2 Terminated
NCT04268277 2026-02-27
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
Phase 2 Terminated
NCT04438382 2026-02-27
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT03417739 2026-02-25
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03801369 2026-02-25
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01885949 2026-02-24
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
NCT03785210 2026-02-23
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT05567835 2026-02-23
TOGAR
Baylor College of Medicine
Phase 2 Terminated
NCT03366766 2026-02-20
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT03990961 2026-02-20
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
University of Chicago
Phase 2 Terminated
NCT03165721 2026-02-18
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02738606 2026-02-17
Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04515004 2026-02-17
Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer
VA Office of Research and Development
Phase 2 Terminated
NCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT05366842 2026-01-30
Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care
Johns Hopkins University
Phase 2 Terminated
NCT05814666 2026-01-30
PEMDA-HN
Flamingo Therapeutics NV
Phase 2 Terminated
NCT04095689 2026-01-23
INTEGRAL
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT03289039 2026-01-22
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05746481 2026-01-22
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
University of Pittsburgh
Phase 2 Terminated
NCT06865677 2026-01-21
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04150029 2026-01-13
STIMULUS-AML1
Novartis
Phase 2 Terminated
NCT05082025 2026-01-09
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05799079 2026-01-09
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03425331 2026-01-08
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT04163718 2026-01-06
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT04578106 2026-01-06
ELPIS
Fundacio Clinic Barcelona
Phase 2 Terminated
NCT03844750 2025-12-31
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
University of California, San Francisco
Phase 2 Terminated
NCT04601857 2025-12-31
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Taiho Oncology, Inc.
Phase 2 Terminated
NCT05267106 2025-12-30
FIGHT-209
Incyte Corporation
Phase 2 Terminated